Results 81 to 90 of about 51,562 (315)

The diagnosis and management of the haematologic manifestations of lupus [PDF]

, 2016
Haematological manifestations in systemic lupus erythematosus (SLE) are frequently observed. They are diverse and range from mild to severe.
Castro, SG, Isenberg, DA, Velo-García, A   +2 more
core   +1 more source

Hetrombopag: A promising thrombopoietin receptor agonist for the treatment of primary and secondary immune thrombocytopenia

Rheumatology &Autoimmunity, EarlyView.
This review seeks to provide a thorough synthesis of the existing literature on the role of thrombopoietin receptor agonists in the treatment of primary and secondary immune thrombocytopenia, with particular emphasis on the compound Hetrombopag. Abstract Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by a platelet count below
Jiaqi Hu, Zhida Fu, Xia Xu, Zhengyi Jin, Xinyu Qian, Weiyu Tao, Taiyan Ma, Dongbao Zhao, Jie Gao   +8 more
wiley   +1 more source

Histopathology DatasetGAN: Synthesizing Large-Resolution Histopathology Datasets [PDF]

arXiv, 2022
Self-supervised learning (SSL) methods are enabling an increasing number of deep learning models to be trained on image datasets in domains where labels are difficult to obtain. These methods, however, struggle to scale to the high resolution of medical imaging datasets, where they are critical for achieving good generalization on label-scarce medical ...
arxiv  

How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance

British Journal of Haematology, Volume 206, Issue 6, Page 1560-1570, June 2025.
The use of rituximab as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is the current standard of care. However, for patients refractory to rituximab or for those with contraindication, further treatment guidelines are scarce.
Julia Weisinger, Jehane Fadlallah, Bérangère Joly, Agnès Veyradier, Paul Coppo   +4 more
wiley   +1 more source

Caplacizumab in the Treatment of Patients with Recurrent Thrombotic Thrombocytopenic Purpura (TTP) [PDF]

Documenta Haematologica
We report two cases of recurrent thrombotic thrombocytopenic purpura, both patients without significant personal pathological antecedents, in which the evolution was favorable following the association of Caplacizumab with the classic treatment with ...
Mihaela-Sabrina HERDEA, Adela-Sara IONESCU, Oana PATRINOIU, Mihaela ANDREESCU   +3 more
doaj   +1 more source

Daratumumab for immune thrombotic thrombocytopenic purpura

Blood Advances, 2021
Key Points Treatment of iTTP with daratumumab leads to disappearance of ADAMTS13 inhibitor and restoration of normal ADAMTS13 activity. Targeting of plasma cells with daratumumab is a new treatment option in relapsing and refractory iTTP.
J. van den Berg, J. K. Kremer Hovinga, C. Pfleger, I. Hegemann, G. Stehle, A. Holbro, J. Studt   +6 more
semanticscholar   +1 more source

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology.
Mark W. Skinner, Manuela Albisetti, Jesús Ardila, Jan Astermark, Jan Blatny, Manuel Carcao, Pratima Chowdary, Nathan T. Connell, Miguel Crato, Yesim Dargaud, Roseline d'Oiron, Amy L. Dunn, Miguel A. Escobar, Carmen Escuriola‐Ettingshausen, Emna Gouider, Annie Harroche, Cedric Hermans, Victor Jimenez‐Yuste, Radoslaw Kaczmarek, Gili Kenet, Liane Khoo, Robert Klamroth, Florian Langer, David Lillicrap, Johnny Mahlangu, Christoph Male, Tadashi Matsushita, Sandrine Meunier, Wolfgang Miesbach, Beatrice Nolan, Johannes Oldenburg, Brian O'Mahony, Margareth Ozelo, Glenn F. Pierce, Gloria Ramos, Michael Recht, Olivia Romero‐Lux, Dawn Rotellini, Rita C. Santoro, Tammuella C. Singleton, Alok Srivastava, Sophie Susen, Kate Talks, Huyen Tran, Leonard A. Valentino, Jerzy Windyga, Renchi Yang, Maria Elisa Mancuso, also on behalf of AICE, AHAD‐AP, AHCDC, ATHN, CLAHT, EHC, French CRH & MHEMO, HTCCNC, NBDF, PEDNET, UKHCDO, WFH   +59 more
wiley   +1 more source

Evaluating the appropriateness of fresh frozen plasma transfusions in two tertiary teaching hospitals

Transfusion Medicine, EarlyView.
Abstract Background Despite efforts to standardise practice using evidence‐based guidelines, fresh frozen plasma (FFP) remains the blood component most frequently prescribed inappropriately. This study assessed the appropriateness of FFP transfusion in two tertiary teaching hospitals and analysed the characteristics of appropriate and inappropriate ...
Jongmin Kim, Kae Lyang Koo, Hyun‐Ji Lee, Hyung‐Hoi Kim   +3 more
wiley   +1 more source

Rare Presentation of Refractory Thrombotic Thrombocytopenic Purpura: Jejunal Stricture

International Journal of Hematology-Oncology and Stem Cell Research, 2017
Thrombotic thrombocytopenic purpura is a rare thrombotic disease characterized by episodes of thrombocytopenia and microangiopathic hemolytic anemia due to disseminated microvascular thrombosis.
Prabath K. Abeysundara, Inoshi Atukorala, K. P. C. Dalpatadu, Karthiha Balendran, M. D. S. A. Dilrukshi, G M O Fernando   +5 more
doaj  

Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis, 2020
Congenital thrombotic thrombocytopenic purpura (cTTP), otherwise known as Upshaw‐Schulman syndrome, is an extremely rare hereditary disease. Pregnancy is identified as a trigger for TTP episodes in patients with cTTP.
K. Sakai, Y. Fujimura, Yasuyuki Nagata, S. Higasa, M. Moriyama, A. Isonishi, M. Konno, M. Kajiwara, Y. Ogawa, Shigehiko Kaburagi, T. Hara, K. Kokame, T. Miyata, K. Hatakeyama, M. Matsumoto   +14 more
semanticscholar   +1 more source